MIRA Pharmaceuticals (MIRA) Insider Nanji Buys 50,000 Shares

MIRA Pharmaceuticals Insider Activity

Insider Shekhat Denil Nanji purchased 50,000 shares of MIRA Pharmaceuticals, Inc. (NasdaqCM: MIRA) on June 12, 2026. This transaction was not an isolated event. On the exact same date, several other insiders stepped in to acquire shares. Whalen Matthew Pratt, Matthew Paul Del Giudice, and Edward Clouston Macpherson each picked up 50,000 shares of the company stock as well. These filings show insiders building up their holdings during a period of transition for the healthcare developer.

MIRA Pharmaceuticals Stock Trading Range

The shares recently changed hands at a spot price of $0.93. That places the equity well above its 52-week low of $0.60, though it remains below the 52-week high of $2.45. Market watchers often look at moving averages to gauge momentum. Here, the 50-day moving average rests at $0.80, while the longer-term 200-day moving average sits higher at $1.08. The equity moves within this corridor as the market weighs the firm's pipeline progress.

Insider Buying and Selling at MIRA Pharmaceuticals, Inc.

The June 12 transactions involved multiple participants acquiring identical blocks of equity. Shekhat Denil Nanji secured 50,000 shares. Whalen Matthew Pratt added 50,000 shares in a pair of filings. Matthew Paul Del Giudice also took on 50,000 shares across multiple reports, and Edward Clouston Macpherson secured 50,000 shares. None of these reported trades indicated use of a pre-arranged Rule 10b5-1 plan.

Analysts Set New Price Targets

Wall Street firms have also begun weighing in on the company's prospects. On September 17, 2026, Maxim Group initiated coverage on the stock with a buy rating and a $3.50 price target. This single opinion forms the current consensus tracked for the equity, giving a target mean price of $3.50 with estimates ranging from a low of $3.50 to a high of $3.50.

About the Company

MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company based in Miami, Florida. The firm focuses on two neuroscience programs targeting neurological and neuropsychiatric disorders. Its pipeline features Ketamir-2, an oral NMDA receptor modulator that finished a Phase 1 clinical trial, alongside MIRA-55 for anxiety and cognitive decline, and SKNY-1 for obesity and nicotine dependence. These programs drive the long-term research focus behind the development efforts.

What to Watch at MIRA

Observers will monitor upcoming regulatory updates and future Form 4 disclosures to see if additional insiders adjust their holdings. Because insider transactions and 13F filings look backward, investors generally check subsequent announcements for shifts in strategy. The company operates without a dividend, leaving capital appreciation tied directly to its clinical milestones and market sentiment.